Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26349201 | 0.85 | KDM4E (0.49) | ALDH1A1TSHRHPGDMEN1KMT2A | |
| SCHEMBL26349189 | 0.82 | MGMT (0.42) | ALDH1A1SMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL29199650 | 0.82 | HPGD (0.49) | ALDH1A1TSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL13159369 | 0.81 | ALDH1A1 (0.58) | ALDH1A1TSHRENPP2SMN1; SMN2POLB | |
| SCHEMBL26349215 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TSHRPOLBHPGD | |
| SCHEMBL14499669 | 0.81 | HPGD (0.50) | ALDH1A1TSHRSMN1; SMN2NPC1RAB9A | |
| SCHEMBL26349212 | 0.78 | MGMT (0.34) | ALDH1A1TSHRNPC1RAB9AHPGD | |
| SCHEMBL26349204 | 0.77 | ALDH1A1 (0.45) | ALDH1A1POLBHPGDTDP1MEN1 | |
| SCHEMBL25495612 | 0.72 | MGMT (0.42) | — | |
| SCHEMBL10491216 | 0.72 | ALDH1A1 (0.82) | ALDH1A1TSHRENPP2SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | SIGILON THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | SIGILON THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | CYP3A43, CYP2C9, CYP2C19 | ALDH1A1 296/4885TSHR 3057/4885ENPP2 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.